Every Spin-Off
Syn2bio
S2BCompletedEUSynektik's biotech R&D arm; lead asset SYN2 cardiac biomarker in phase 3 trials. 1:1 ratio, 8,529,129 shares.
- Distribution date
- 15 Apr 2026
- Structure
- Spin-off
- Parent
- Synektik (SNT)
- Spin-off ticker
- S2B
- Listing
- GPW Main Market (Warsaw)
- Market
- Europe
- Size
- Assets transferred ~PLN 163m (book, ~7.7% of Synektik equity value)
Source documents
- Press releaseNot located
- PresentationNot located
- Prospectus / demerger documentNot located
- Sourcestrefainwestorow.pl
- Sourcebiznesradar.pl
- Sourceparkiet.com
Every Spin-Off research
No report on this situation yet. New reports are published on Substack first.
Receive reports by email